NMN human exam results at the University of Tokyo School of Medicine
NMN research at the University of Tokyo Hospital
A research team by assistant professor Masaki Igarashi and others at the University of Tokyo Hospital has confirmed the effect of improving the grip and walking speed of NMN's healthy elderly men. This study was conducted for 42 healthy men over the age of 65 (average age 71.5 years), and the subjects were randomly divided into NMN groups and placebo groups, and 250 mg per day was administered for 12 weeks. As a result, in the NMN group, the blood NAD concentration increased more than twice as much as the placebo group, and no adverse events were confirmed.
The grip and walking speed are the progressive indicators of sarcopenia (muscle hypothermia), indicating that NMN can contribute to the prevention of sarcopenia. In addition, NAD increases NAD and activates sustain enzymes, which is expected to have the effect of controlling aging.
NMN research at the University of Tsukuba
A similar study was conducted at the University of Tsukuba, and NMN or Plasebo was administered for 108 men and women over 65 years old (average age 72.6 years) for 12 weeks. This study reported that the NMN intake group had significantly improved lower body strength and sleep quality, and is likely to suppress aging of the athletic function for the elderly.
Further research and expectation of NMN
In future research, we plan to verify the further improvement of motor function and muscle strength by extending the dose period of NMN and increasing the dose. It is also suggested that NMN may contribute to hearing improvement, and is expected to prevent dementia.
Igarashi -assistant emphasizes that NMN has a low risk of cancer and is high, and to further pursue NMN's anti -aging effects, the prevention of sarcopenia in super -aged society and extend health life expectancy. We aim to contribute to. We are also working on NMN's prices and quality issues, aiming to make it available to more people.
A research team by assistant professor Masaki Igarashi and others at the University of Tokyo Hospital has confirmed the effect of improving the grip and walking speed of NMN's healthy elderly men. This study was conducted for 42 healthy men over the age of 65 (average age 71.5 years), and the subjects were randomly divided into NMN groups and placebo groups, and 250 mg per day was administered for 12 weeks. As a result, in the NMN group, the blood NAD concentration increased more than twice as much as the placebo group, and no adverse events were confirmed.
The grip and walking speed are the progressive indicators of sarcopenia (muscle hypothermia), indicating that NMN can contribute to the prevention of sarcopenia. In addition, NAD increases NAD and activates sustain enzymes, which is expected to have the effect of controlling aging.
NMN research at the University of Tsukuba
A similar study was conducted at the University of Tsukuba, and NMN or Plasebo was administered for 108 men and women over 65 years old (average age 72.6 years) for 12 weeks. This study reported that the NMN intake group had significantly improved lower body strength and sleep quality, and is likely to suppress aging of the athletic function for the elderly.
Further research and expectation of NMN
In future research, we plan to verify the further improvement of motor function and muscle strength by extending the dose period of NMN and increasing the dose. It is also suggested that NMN may contribute to hearing improvement, and is expected to prevent dementia.
Igarashi -assistant emphasizes that NMN has a low risk of cancer and is high, and to further pursue NMN's anti -aging effects, the prevention of sarcopenia in super -aged society and extend health life expectancy. We aim to contribute to. We are also working on NMN's prices and quality issues, aiming to make it available to more people.